JOHNSON & JOHNSON Q4 2025 Filing

Filed February 13, 2026

Portfolio Value

$554.6M

Holdings

17

Report Date

Q4 2025

Filing Type

13F-HR

All Holdings (17 positions)

#StockSharesValue% PortfolioType
1
PTGXProtagonist Therapeutics Inc.
2,449,183$213.9M38.57%
2
NBTXNanobiotix S.A.
5,623,816$130.0M23.44%
3
RAPPRapport Therapeutics, Inc.
1,784,517$54.1M9.76%
4
MGTXMeiraGTx Holdings plc
6,641,064$52.8M9.52%
5
CVRXCVRx, Inc.
4,024,861$28.6M5.15%
6
CTNMContineum Therapeutics Inc.
1,979,173$22.6M4.08%
7
LEGNLegend Biotech Corporation
814,586$17.7M3.19%
8
XNCRXencor, Inc.
748,062$11.5M2.06%
9
PRCTProcept BioRobotics Corporation
357,939$11.3M2.03%
10
FATEFate Therapeutics, Inc.
3,379,064$3.3M0.60%
11
NMRANeumora Therapeutics, Inc.
1,849,445$3.3M0.60%
12
RLYBRallybio Corporation
3,636,363$2.5M0.45%
13
LYELLyell Immunopharma, Inc.
41,165$1.3M0.23%
14
VORVor Biopharma, Inc.
53,732$702K0.13%
15
NNOXNano-X Imaging Ltd.
158,852$444K0.08%
16
FLBStandard BioTools, Inc.
311,967$399K0.07%
17
ACETAdicet Bio, Inc.
22,779$191K0.03%